GENI.LSE

Genincode PLC

GENI.LSE, UK

GENinCode Plc develops and commercializes clinical genetic tests to provide predictive analysis of risk to a patient's health based on their genes in the United Kingdom and internationally. Its predictive technology offers patients and physicians with preventative care and treatment strategies. The company's invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset. Its tests include Cardio inCode, a genetic test to help user to adopt cardiovascular prevention assesment; Lipid inCode, a genetic diagnostic test for familial hypercholesterolemia FH; SUDD inCode, genetic diagnostic test for familial heart diseases; Thrombo inCode, a genetic test for diagnosis of hereditary thrombophilia and the risk of thrombosis. In addition, the company offers Thrombo inCode Reproductive Health, is a genetic test that evaluates the impact of hereditary thrombophilia in patients with repeated miscarriages; and ROCA Test, a blood test that determines the risk of a woman having ovarian cancer. Further, it engages in the medical and scientific research activities. GENinCode Plc was incorporated in 2018 and is based in Manchester, the United Kingdom.

https://www.genincode.com

Stock Price

GBp 0.00

0%

increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
GENI.LSE
stock
GENI.LSE

Genincode Share Price (GENI) London South East

Read more →
GENI.LSE
stock
GENI.LSE

What is the FTSE 100 index? MarketBeat

Read more →

Finn Analysis

(Last Updated 2025-06-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

187.02

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-111.27 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-70.20 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-200.69 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Medium

0.59

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of Genincode PLC

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

No earnings data available.

Investing Fit Scorecard

(Last Updated 2025-06-30)

Deep Value
Potential Value Candidate(4)
Defensive
Highly Defensive(6.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Fair GARP(3.5)
Growth
Weak Growth Prospect(2.5)
Momentum
Moderate Momentum(5.5)
Net Net
Not Undervalued (Net-Net)(3)
Quality
Low Quality Business(2.5)
Value
Fair Value(4.5)

Income Statement

(Last Updated 2025-06-30)

Revenue

£ 0

Cost Of Revenue

£ 0

Gross Profit

£ 0

Operating Expenses

£ 0

Operating Income

£ 0

Interest Expense

£ 0

Pretax Income

£ 0

Net Income

£ 0

Income Tax Expense

£ 0

EBITDA

£ 0

Total Other Income Expense Net

£ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-06-30)

Cash

£ 0

Short Term Investments

£ 0

Receivables

£ 0

Inventories

£ 0

Total Current Assets

£ 0

Property Plant Equipment

£ 0

Total Assets

£ 0

Payables

£ 0

Short Term Debt

£ 0

Long Term Debt

£ 0

Total Liabilities

£ 0

Equity

£ 0

Trend

Cash Flow

(Last Updated 2025-06-30)

Net Income

£ 0

Depreciation

£ 0

Change In Working Capital

£ 0

Cash From Operations

£ 0

Capital Expenditures

£ 0

Cash From Investing

£ 0

Cash From Financing

£ 0

Net Change In Cash

£ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.